pharma is the sole category represented across all 1 tracked stories. Jaime Olin is most often covered alongside Elizabeth Brannen, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Jaime Olin appears in 1 tracked Biotech story from August 24, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jaime Olin
pharma is the sole category represented across all 1 tracked stories. Jaime Olin is most often covered alongside Elizabeth Brannen, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Jaime Olin appears in 1 tracked Biotech story from August 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jaime Olin. Shared-story counts are live from our verified record — not editorial picks.
Stris & Maher's four-partner team adds Hatch-Waxman, PTAB, and biological sciences depth, giving biopharma companies expanded counsel for patent disputes across branded and generic markets.